Edison Explains Psychedelics
Updated: Nov 9, 2021
Edison Group looks at the ongoing revolution of hallucinogenic drug research. Edison’s Sean Conroy states that recent preliminary clinical evidence has shown psilocybin to have significant improvements over the available therapy for treatment-resistant depression and major depressive disorder.
#mentalhealth#psychedelicscience
https://www.linkedin.com/feed/update/urn:li:activity:6854682081453248512
Edison-explains-Psychedelics-Final-draft-2-_0-1
.pdf
Download PDF • 206KB
